Update on Myelodysplastic Syndromes (MDS): Diagnosis, Treatment & Support
 

The Leukemia & Lymphoma Society (LLS) is monitoring closely the coronavirus (COVID-19) outbreak. As a health organization, one of our highest priorities is the well-being of the patients we serve, as well as our employees, volunteers, donors and partners.  We are following vigilantly U.S. Centers for Disease Control and Prevention (CDC) guidelines to evaluate our plans, including upcoming events, in order to act in a timely and responsible way.

Out of an abundance of caution and prioritizing the safety for our patients, speakers, attendees, staff and volunteers, The Leukemia & Lymphoma Society is postponing this program, "Update on Myelodysplastic Syndromes (MDS): Diagnosis, Treatment & Support" previously scheduled on March 17, 2020. We will update registrants and this website when the new date is scheduled.

We’re here to help. As the leading source of free blood cancer information, education and support for patients, survivors, caregivers, families and healthcare professionals, we are committed to patients and families throughout their entire cancer experience. Our Information Specialists – master’s level oncology professionals – are available to guide patients and caregivers with one-on-one support. Contact an LLS Information Specialist for at 1.800.955.4572, and by live chat or email via www.LLS.org.

 

We also encourage patients and families to read “4 Things Every Cancer Patient Needs to Know about the Coronavirus” by LLS Chief Medical Officer Dr. Gwen Nichols on The LLS Blog.

 

 

Welcome to

Update on Myelodysplastic Syndromes (MDS): Diagnosis, Treatment & Support

March 17, 2020

Radisson Red Portland Downtown - Studio One

1455 SW Broadway, Portland, OR, 97201

 

Time: 6:00 - 8:00 pm

Check-in & Dinner: 6:00 - 6:30 pm

Program: 6:30 - 8:00 pm

Complimentary dinner will be provided. Please register in advance.

Speaker

GABRIELLE MEYERS, MD

OHSU CENTER FOR HEMATOLOGIC MALIGNANCIES

OHSU ASSOCIATE PROFESSOR OF MEDICINE, SCHOOL OF MEDICINE

 

Program
 

This in-person program will provide an overview of Myelodysplastic Syndromes (MDS), focusing on diagnosis, strategies for management, and support modalities. Risk assessment, treatment options, the role of various members of the healthcare team in addressing treatment goals, guidance for patients and caregivers in treatment decision making, as well as resources for patients and caregivers will be discussed.
 
 
Continuing Education (CE) Information 

Goal

To provide a learning opportunity for oncology nurses and other healthcare professionals to expand their knowledge about the diagnosis, treatment, and support of patients with Myelodysplastic Syndromes (MDS).

 

Objectives 

AT THE CONCLUSION OF THIS PROGRAM, PARTICIPANTS WILL BE ABLE TO:

  • Describe clinical presentation, diagnostic workup, and prognostication for MDS
  • Differentiate lower and higher risk MDS features, current management strategies, and emerging treatment options
  • Explain the role of genetic testing in risk assessment for patients
  • Discuss the roles of a multidisciplinary healthcare team in addressing treatment goals and providing patient education to improve outcomes, including guiding patients and caregivers in decision making, financial issues, and palliative care options
  • Identify resources for support and education for patients

 

Target Audience

Oncology nurses and other healthcare professionals at the intermediate level of practice, involved in the care of patients with Myelodysplastic Syndromes (MDS) 

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

 
 

Upon completion of this program and submission of the activity evaluation, a certificate of completion will be emailed to you within 30 days.

 

 
To register, please click on the REGISTER tab above.